Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - General | USA
statements
IndexDJIA S&P500 P/E19.29 EPS (ttm)3.98 Insider Own0.10% Shs Outstand2.53B Perf Week-1.83%
Market Cap191.95B Forward P/E12.63 EPS next Y6.07 Insider Trans-4.29% Shs Float2.52B Perf Month-6.77%
Income10.20B PEG3.22 EPS next Q1.05 Inst Own77.50% Short Float0.58% Perf Quarter-6.04%
Sales48.08B P/S3.99 EPS this Y58.90% Inst Trans-1.05% Short Ratio1.36 Perf Half Y-13.44%
Book/sh10.35 P/B7.41 EPS next Y14.57% ROA12.10% Target Price93.00 Perf Year-9.58%
Cash/sh2.97 P/C25.83 EPS next 5Y6.00% ROE38.10% 52W Range65.25 - 92.64 Perf YTD-15.68%
Dividend2.44 P/FCF61.35 EPS past 5Y-1.10% ROI19.20% 52W High-17.22% Beta0.49
Dividend %3.18% Quick Ratio0.90 Sales past 5Y2.10% Gross Margin72.20% 52W Low17.53% ATR1.76
Employees71000 Current Ratio1.10 Sales Q/Q11.50% Oper. Margin25.50% RSI (14)45.86 Volatility1.83% 2.31%
OptionableYes Debt/Eq1.07 EPS Q/Q10.30% Profit Margin21.10% Rel Volume0.71 Prev Close77.92
ShortableYes LT Debt/Eq0.83 EarningsJul 31 BMO Payout58.30% Avg Volume10.73M Price76.69
Recom2.00 SMA20-0.72% SMA50-2.02% SMA200-6.94% Volume7,598,555 Change-1.58%
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Jul-09-20 04:30PM  
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
Business Wire
11:44AM  
Coronavirus vaccine makers to testify before U.S. House committee
Reuters
08:53AM  
New $1 billion fund aims to steer antibiotic companies in tough market
Reuters
08:45AM  
New $1 billion fund aims to steer antibiotic companies in tough market
Reuters
08:40AM  
New $1 bln fund aims to steer antibiotic companies in tough market
Reuters
08:13AM  
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
Zacks
07:00AM  
Prominent plaintiffs' firms sought government bailout to stay afloat
Reuters
06:45AM  
FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Business Wire
Jul-08-20 04:30PM  
Merck Announces Appointment of Organon & Co. General Counsel
Business Wire
01:21PM  
Dow Inc., American Express share losses lead the way, but Dow flat
MarketWatch
11:30AM  
Where COVID-19 vaccine trials stand
Yahoo Finance Video
11:29AM  
Immunomedics: A Solid Cancer Research Play
GuruFocus.com
07:38AM  
Merck, Eisai to put experimental cancer combination in new clinical trial
MarketWatch
07:01AM  
FDA declines to approve Merck and Eisai's liver cancer combo therapy
Reuters
06:55AM  
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
Business Wire
06:45AM  
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Business Wire
02:24AM  
AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer
Reuters
02:15AM  
AstraZeneca-Merck Lynparza wins EU approval for pancreatic cancer
Reuters
Jul-07-20 05:50PM  
Merck (MRK) Stock Moves -1.08%: What You Should Know
Zacks
06:00AM  
U.S. government awards Novavax $1.6 billion for coronavirus vaccine
Reuters
Jul-06-20 06:45AM  
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Business Wire
Jul-03-20 09:24AM  
How Many Merck & Co., Inc. (NYSE:MRK) Shares Do Institutions Own?
Simply Wall St.
Jul-02-20 05:38PM  
Were Hedge Funds Right About Merck & Co., Inc. (MRK)?
Insider Monkey
03:23PM  
Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses
Reuters
01:02PM  
Keep an Eye on Royalty Pharma Stock, 2020s Biggest IPO
InvestorPlace
12:10PM  
Why the Earnings Surprise Streak Could Continue for Merck (MRK)
Zacks
08:21AM  
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Benzinga
02:00AM  
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Business Wire
Jul-01-20 04:30PM  
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
Business Wire
03:24PM  
Dow's 25-point climb highlighted by gains in shares of Pfizer, Walt Disney
MarketWatch
10:45AM  
Dow jumps 25 points on gains for Pfizer, Walt Disney stocks
MarketWatch
06:45AM  
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
Business Wire
Jun-30-20 11:45AM  
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Zacks
10:34AM  
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
Zacks
07:41AM  
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
Benzinga
06:40AM  
High volatility is here to stay in 2020. Goldman names 31 stocks to deliver the best returns amid the turbulence
MarketWatch
Jun-29-20 04:20PM  
FDA Approves Mercks KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
Business Wire
09:36AM  
Covid Changed the Definition of Corporate Leadership. Meet Barrons New Top CEOs.
Barrons.com
07:47AM  
These 6 health-care stocks are buys because they can thrive under either Trump or Biden
MarketWatch
Jun-26-20 09:22PM  
After Building a Cancer-Drug Franchise, Mercks CEO Is Now Tackling Covid-19
Barrons.com
Jun-25-20 03:26PM  
Acquiring Biomarin Would Speed Sanofi Transition to New Therapies
GuruFocus.com
08:26AM  
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Benzinga
Jun-24-20 05:29PM  
FDA Approves Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
Business Wire
06:45AM  
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Business Wire
Jun-23-20 05:50PM  
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Zacks
11:31AM  
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
Zacks
10:45AM  
Merck, Apple Inc. share gains contribute to Dow's nearly 150-point jump
MarketWatch
09:45AM  
JPMorgan Chase, Merck share gains lead Dow's 260-point rally
MarketWatch
07:23AM  
Merck, BioInvent Enroll First Patient In Solid Tumor Combo Trial
SmarterAnalyst
Jun-22-20 12:52PM  
How health data is used to target online ads
Yahoo Finance Video
09:34AM  
Merck Wins Keytruda China Approval; Analyst Applauds First-Mover Advantage
SmarterAnalyst
06:45AM  
Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
Business Wire
06:30AM  
Mercks KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS 10)
Business Wire
Jun-19-20 12:02PM  
Why Growth Investors will Love These 2 Healthcare Stocks
Insider Monkey
08:29AM  
Merck Completes Acquisition of Themis
Business Wire
Jun-18-20 11:35AM  
Merck's Keytruda Gets Accelerated Approval for Solid Tumors
Zacks
10:45AM  
Dow falls 39 points on losses in shares of UnitedHealth, Cisco
MarketWatch
Jun-17-20 05:45PM  
Merck (MRK) Dips More Than Broader Markets: What You Should Know
Zacks
04:30PM  
Merck Animal Health Completes Acquisition of Quantified Ag®
Business Wire
02:32PM  
Coronavirus update: U.S. death toll edges above 117,000; Oklahoma is one of 9 states that are still setting case records
MarketWatch
09:52AM  
Stock market tries for 4th straight gain on hope of a V-shaped economic recovery from coronavirus
MarketWatch
09:23AM  
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
Zacks
08:41AM  
Merck prices four-part bond offering
MarketWatch
07:30AM  
The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
Benzinga
06:45AM  
FDA Approves Second Biomarker-Based Indication for Mercks KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
Business Wire
06:30AM  
Merck Prices $4.5 Billion Debt Offering
Business Wire
Jun-16-20 07:00PM  
US Indexes Close Higher Tuesday After Retail Sales Increase 18%
GuruFocus.com
03:07PM  
Caterpillar, Merck share gains contribute to Dow's 484-point rally
MarketWatch
02:06PM  
Dow surges 561 points on gains in Caterpillar, Merck shares
MarketWatch
01:15PM  
Merck and Pfizers SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Business Wire
01:05PM  
U.S. appeals court rejects rule requiring drug prices in TV ads
Reuters
01:01PM  
Caterpillar, Boeing share gains contribute to Dow's 629-point surge
MarketWatch
12:43PM  
Merck & Co., Inc. -- Moody's assigns A1 rating to Merck's new notes; stable outlook
Moody's
12:01PM  
Dow's nearly 450-point rally highlighted by gains for shares of Caterpillar, Boeing
MarketWatch
10:36AM  
U.S. narrows list of promising COVID-19 vaccine candidates to about 7
Reuters
Jun-15-20 05:00PM  
UK funds human trials of potential COVID-19 vaccine from Imperial
Reuters
12:46PM  
Dow drops nearly 125 points on losses in Merck, Home Depot shares
MarketWatch
11:46AM  
Chevron, Boeing share losses contribute to Dow's 359-point drop
MarketWatch
10:46AM  
Merck's Gardasil Gets FDA Approval for Head and Neck Cancers
Zacks
10:45AM  
Dow drops 425 points on losses in shares of Boeing, Chevron
MarketWatch
09:36AM  
Billions or trillions: The great coronavirus trade-off
Yahoo Finance Video
08:00AM  
Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities
Business Wire
01:48AM  
Mercks Gardasil Receives FDA Nod For Expanded Cancer Indications
SmarterAnalyst
Jun-14-20 01:52PM  
Is Merck A Great Dividend Stock?
Motley Fool
Jun-13-20 08:21AM  
Billions or trillions: The great coronavirus trade-off
Yahoo Finance
06:55AM  
Got $1,000? You Might Want To Buy These 2 Coronavirus Stocks Now
Motley Fool
Jun-12-20 06:40PM  
FDA Approves Mercks GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
Business Wire
02:12PM  
Avoid Merck Stock Until Shares Pull Back
InvestorPlace
01:48PM  
Walmart, Intel share losses lead the way, but Dow flat
MarketWatch
10:04AM  
Benzinga's Top Upgrades, Downgrades For June 12, 2020
Benzinga
08:54AM  
J&J exec: Our coronavirus vaccine is aiming for a 70% success rate in trials
Yahoo Finance
Jun-11-20 11:34PM  
Japan's PeptiDream to work with Merck in developing COVID-19 therapies
Reuters -5.41%
11:37AM  
AstraZeneca's R&D Spending Spikes 21% to Industry Best in 2019
GuruFocus.com
Jun-10-20 04:53PM  
Dow closes 280 points lower, Nasdaq above 10,000 after Fed says itll keep buying bonds and interest rates near zero
MarketWatch
09:09AM  
Merck's Keytruda Fails in First-Line Bladder Cancer Study
Zacks
05:02AM  
Mercks Keytruda Fails To Meet Endpoints In Bladder Cancer Trial
SmarterAnalyst
Jun-09-20 04:44PM  
Merck's Keytruda doesn't meet goals in bladder cancer study
MarketWatch
04:28PM  
Roche, Johnson & Johnson Top R&D Spenders in 2019
GuruFocus.com
04:26PM  
Merck's bladder cancer late-stage study fails to meet main goals
Reuters
04:05PM  
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through Pharmaceutical and Animal Health segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products; and dog, cat, and horse vaccines. The company serves drug wholesalers and retailers, hospitals, government agencies, managed health care providers, physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; PeptiDream Inc.; Shanghai Junshi Biosciences Co., Ltd.; Targovax ASA; and Linnaeus Therapeutics, Inc. It also has strategic research collaboration and license agreement with Yumanity Therapeutics. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRUN LESLIE ADirectorMay 07Option Exercise0.005,00006,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Option Exercise0.005,00005,100May 07 04:50 PM
BRUN LESLIE ADirectorMay 07Sale75.465,000377,3001,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Sale76.025,000380,104100May 07 04:50 PM
Nally MichaelEVP, Chief Marketing OfficerMay 05Option Exercise76.862,345180,23712,054May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 05Option Exercise76.863,283252,33129,401May 06 05:15 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 05Option Exercise76.861,29099,1497,304May 06 05:16 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 05Option Exercise76.863,752288,37982,611May 06 05:17 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise77.671,904147,88479,797May 06 05:17 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise77.6769253,7486,252May 06 05:16 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise77.671,21294,13626,715May 06 05:15 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise77.675,772448,3119,489May 06 05:13 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise77.671,298100,81610,274May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise77.6787567,96125,934May 05 04:48 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 03Option Exercise77.671,541119,6896,089May 05 04:42 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Option Exercise0.0082,5480139,111Jan 15 05:15 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Sale89.34102,0739,118,86537,038Jan 15 05:15 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
open in yahoo | open in reuters | open in google